PARP-1 Degradation for Alzheimer's-related Diseases
Official title: PARP-1 Degradation for PARP-Related Diseases
Funded at Queens College · NIH-11384140 · Data updated 2026-11-12
A new approach to lower PARP-1 protein in diseased human cells to help with Alzheimer’s-related dementia and other conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Queens College NIH-funded |
| Lab location | 1 site (Flushing, United States) |
| Project start | August 4, 2025 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $153,363 |
| NIH project number | 5R16GM159645-02 |
| Project ID | NIH-11384140 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with Alzheimer’s disease dementia or related neurodegenerative conditions, or patients who could provide relevant human cell samples for testing.
✕Less likely to help
People whose disease is not driven by PARP-1 dysregulation or who cannot provide suitable cellular material may not benefit.
What this research studies
This project aims to create a new class of PROTACs that degrade PARP-1, a key protein involved in DNA damage response, in human cells affected by neurodegenerative disease. By reducing PARP-1 activity, the research hopes to lessen harmful cellular stress and improve cell survival in conditions like Alzheimer’s disease. The team will design and test PARP-1 degraders, addressing challenges seen with current inhibitors such as off-target effects and resistance. The work is conducted across disciplines to translate laboratory findings toward potential future therapies. If successful, these degraders could offer a novel treatment strategy for Alzheimer’s dementia and related disorders.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that slow or modify disease progression by reducing PARP-1–driven cellular damage.
How similar studies have gone: PARP-1 inhibitors have shown clinical benefit in some contexts, but degraders represent a novel approach with potential to overcome resistance and toxicity issues, with limited prior clinical success for neurodegenerative indications.
Where this research is happening
-
Queens College
Flushing, United States Active
Researchers
- Principal investigator: Pathak, Sanjai Kumar — Queens College
- Study coordinator: Pathak, Sanjai Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.